StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Up 3.0 %
NASDAQ:AEZS opened at $5.51 on Friday. The stock’s 50-day simple moving average is $6.41 and its 200 day simple moving average is $7.34. The firm has a market capitalization of $9.86 million, a PE ratio of -0.37 and a beta of 1.56. Aeterna Zentaris has a twelve month low of $3.96 and a twelve month high of $12.36.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Aeterna Zentaris
- What is the Shanghai Stock Exchange Composite Index?
- Survey: Top 175 Fittest Retirement Locations in America
- Election Stocks: How Elections Affect the Stock Market
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Consumer Discretionary Stocks Explained
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.